drugset / Trial / NCT03458728

Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients

NCT03458728

Phase 1/2 Terminated 31 enrolled Bayer
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study is designed to investigate whether the use of copanlisib is safe, feasible and beneficial to pediatric patients with solid solid tumors or lymphoma that are recurrent or refractory to standard therapy.

Timeline

Start
2018-04-30
Primary completion
2023-02-01
Completion
2023-02-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Copanlisib Small molecule